ICUI

SEC source: 0001804831-20-000003 · edgardoc.xml · nonDerivative · entry 1

Bonnell Brian Michael · CIK 0001804831 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 722

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001375852-20-000004 · edgardoc.xml · derivative · entry 3

Lamb Scott E · CIK 0001375852 · Chief Financial Officer,

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,005

Underlying: Common Stock · 1,006 shares

Expires 2021-02-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: These Securities are Performance-based Restricted Stock Units (PRSU).

F2 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the PRSUs.

F3 · derivative.exercise_date: These PRSUs were granted on March 6, 2018. Vesting of these performance stock units are subject to the satisfaction of both performance-based conditions and time-based criteria. These PRSUs vest on February 15 of the first, second, and third year following the year of grant.

SEC source: 0001375852-20-000004 · edgardoc.xml · nonDerivative · entry 2

Lamb Scott E · CIK 0001375852 · Chief Financial Officer,

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,274

SEC source: 0001375852-20-000004 · edgardoc.xml · nonDerivative · entry 1

Lamb Scott E · CIK 0001375852 · Chief Financial Officer,

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,803

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001669639-20-000004 · edgardoc.xml · derivative · entry 3

Sanzone Virginia Ruth · CIK 0001669639 · VP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,005

Underlying: Common Stock · 1,006 shares

Expires 2021-02-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: These Securities are Performance-based Restricted Stock Units (PRSU).

F2 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the PRSUs.

F3 · derivative.exercise_date: These PRSUs were granted on March 6, 2018. Vesting of these performance stock units are subject to the satisfaction of both performance-based conditions and time-based criteria. These PRSUs vest on February 15 of the first, second, and third year following the year of grant.

SEC source: 0001669639-20-000004 · edgardoc.xml · nonDerivative · entry 2

Sanzone Virginia Ruth · CIK 0001669639 · VP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 532

SEC source: 0001669639-20-000004 · edgardoc.xml · nonDerivative · entry 1

Sanzone Virginia Ruth · CIK 0001669639 · VP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,061

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001698998-20-000005 · edgardoc.xml · derivative · entry 6

Woolson Daniel · CIK 0001698998 · VP, GM-Infusion Capital

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 804

Underlying: Common Stock · 805 shares

Expires 2021-02-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · security: These Securities are Performance-based Restricted Stock Units (PRSU).

F5 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the PRSUs.

F6 · derivative.exercise_date: These PRSUs were granted on March 6, 2018. Vesting of these performance stock units are subject to the satisfaction of both performance-based conditions and time-based criteria. These PRSUs vest on February 15 of the first, second, and third year following the year of grant.

SEC source: 0001698998-20-000005 · edgardoc.xml · nonDerivative · entry 4

Woolson Daniel · CIK 0001698998 · VP, GM-Infusion Capital

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,200

SEC source: 0001698998-20-000005 · edgardoc.xml · nonDerivative · entry 3

Woolson Daniel · CIK 0001698998 · VP, GM-Infusion Capital

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,556

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001698998-20-000005 · edgardoc.xml · derivative · entry 5

Woolson Daniel · CIK 0001698998 · VP, GM-Infusion Capital

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,282 shares

Expires 2020-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: These securities are Restricted Stock Units.

F2 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the Restricted Stock Units.

F3 · derivative.exercise_date: One third of the units subject to the award shall vest on each of the first, second, and third anniversaries of the grant date.

SEC source: 0001698998-20-000005 · edgardoc.xml · nonDerivative · entry 2

Woolson Daniel · CIK 0001698998 · VP, GM-Infusion Capital

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,751

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001698998-20-000005 · edgardoc.xml · nonDerivative · entry 1

Woolson Daniel · CIK 0001698998 · VP, GM-Infusion Capital

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,469

SEC source: 0001669639-20-000002 · edgardoc.xml · nonDerivative · entry 1

Sanzone Virginia Ruth · CIK 0001669639 · VP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 25, 2019.

F2 · price: All shares sold were sold at the exact price disclosed.

SEC source: 0001073398-20-000002 · edgardoc.xml · derivative · entry 4

SWINNEY ROBERT S · CIK 0001073398 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,500 shares

Expires 2020-02-03

F3 · derivative.exercise_date: These stock options vest on the anniversary of the date of the grant or the following annual stockholder meeting, whichever occurs first.

SEC source: 0001073398-20-000002 · edgardoc.xml · nonDerivative · entry 2

SWINNEY ROBERT S · CIK 0001073398 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,704

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2019.

F2 · price: All shares sold were sold at the exact price disclosed.

SEC source: 0001073398-20-000002 · edgardoc.xml · nonDerivative · entry 1

SWINNEY ROBERT S · CIK 0001073398 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,972

SEC source: 0001698998-20-000003 · edgardoc.xml · nonDerivative · entry 2

Woolson Daniel · CIK 0001698998 · VP, GM-Infusion Capital

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,479

SEC source: 0001698998-20-000003 · edgardoc.xml · derivative · entry 4

Woolson Daniel · CIK 0001698998 · VP, GM-Infusion Capital

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,181 shares

Expires 2019-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: These Securities are Performance-based Restricted Stock Units (PRSU).

F3 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the PRSUs.

F4 · shares: Each PRSU reflects the contingent right to receive a variable number of shares of common stock based on achieving performance goals. At the determination date, based on certification of the achievement of the performance criteria, the reporting person earned 300% of the target award amount.

F1 · derivative.exercise_date: These PRSUs were granted on March 27, 2017. The vesting for this performance-based restricted stock unit ("PRSU") award was dependent upon the achievement of a minimum Cumulative Adjusted EBITDA over the Fiscal Years 2017-2019. The reporting person was able to earn PRSUs ranging from 100% to 300% of the target award amount.

SEC source: 0001698998-20-000003 · edgardoc.xml · nonDerivative · entry 1

Woolson Daniel · CIK 0001698998 · VP, GM-Infusion Capital

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,478

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001615186-20-000001 · edgardoc.xml · derivative · entry 3

McCall Thomas D · CIK 0001615186 · Vice President and Gen'l Mgr.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,153 shares

Expires 2019-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: These Securities are Performance-based Restricted Stock Units (PRSU).

F2 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the PRSUs.

F3 · shares: Each PRSU reflects the contingent right to receive a variable number of shares of common stock based on achieving performance goals. At the determination date, based on certification of the achievement of the performance criteria, the reporting person earned 300% of the target award amount.

F4 · derivative.exercise_date: These PRSUs were granted on March 27, 2017. The vesting for this performance-based restricted stock unit ("PRSU") award was dependent upon the achievement of a minimum Cumulative Adjusted EBITDA over the Fiscal Years 2017-2019. The reporting person was able to earn PRSUs ranging from 100% to 300% of the target award amount.

SEC source: 0001615186-20-000001 · edgardoc.xml · nonDerivative · entry 2

McCall Thomas D · CIK 0001615186 · Vice President and Gen'l Mgr.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,841

SEC source: 0001615186-20-000001 · edgardoc.xml · nonDerivative · entry 1

McCall Thomas D · CIK 0001615186 · Vice President and Gen'l Mgr.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,539

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001375852-20-000002 · edgardoc.xml · derivative · entry 3

Lamb Scott E · CIK 0001375852 · Chief Financial Officer,

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,334 shares

Expires 2019-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: These Securities are Performance-based Restricted Stock Units (PRSU).

F2 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the PRSUs.

F3 · shares: Each PRSU reflects the contingent right to receive a variable number of shares of common stock based on achieving performance goals. At the determination date, based on certification of the achievement of the performance criteria, the reporting person earned 300% of the target award amount.

F4 · derivative.exercise_date: These PRSUs were granted on March 27, 2017. The vesting for this performance-based restricted stock unit ("PRSU") award was dependent upon the achievement of a minimum Cumulative Adjusted EBITDA over the Fiscal Years 2017-2019. The reporting person was able to earn PRSUs ranging from 100% to 300% of the target award amount.

SEC source: 0001375852-20-000002 · edgardoc.xml · nonDerivative · entry 2

Lamb Scott E · CIK 0001375852 · Chief Financial Officer,

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,797

SEC source: 0001375852-20-000002 · edgardoc.xml · nonDerivative · entry 1

Lamb Scott E · CIK 0001375852 · Chief Financial Officer,

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,643

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001727477-20-000001 · edgardoc.xml · derivative · entry 3

Voigtlander Christian B. · CIK 0001727477 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,334 shares

Expires 2019-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: These Securities are Performance-based Restricted Stock Units (PRSU).

F3 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the PRSUs.

F2 · shares: Each PRSU reflects the contingent right to receive a variable number of shares of common stock based on achieving performance goals. At the determination date, based on certification of the achievement of the performance criteria, the reporting person earned 300% of the target award amount.

F4 · derivative.exercise_date: These PRSUs were granted on March 27, 2017. The vesting for this performance-based restricted stock unit ("PRSU") award was dependent upon the achievement of a minimum Cumulative Adjusted EBITDA over the Fiscal Years 2017-2019. The reporting person was able to earn PRSUs ranging from 100% to 300% of the target award amount.

SEC source: 0001727477-20-000001 · edgardoc.xml · nonDerivative · entry 2

Voigtlander Christian B. · CIK 0001727477 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,321

SEC source: 0001727477-20-000001 · edgardoc.xml · nonDerivative · entry 1

Voigtlander Christian B. · CIK 0001727477 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,166

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: These Securities are Performance-based Restricted Stock Units (PRSU).

F2 · shares: Each PRSU reflects the contingent right to receive a variable number of shares of common stock based on achieving performance goals. At the determination date, based on certification of the achievement of the performance criteria, the reporting person earned 300% of the target award amount.

SEC source: 0001375852-20-000001 · edgardoc.xml · derivative · entry 3

Sanzone Virginia Ruth · CIK 0001669639 · VP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,334 shares

Expires 2019-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: These Securities are Performance-based Restricted Stock Units (PRSU).

F2 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the PRSUs.

F3 · shares: Each PRSU reflects the contingent right to receive a variable number of shares of common stock based on achieving performance goals. At the determination date, based on certification of the achievement of the performance criteria, the reporting person earned 300% of the target award amount.

F4 · derivative.exercise_date: These PRSUs were granted on March 27, 2017. The vesting for this performance-based restricted stock unit ("PRSU") award was dependent upon the achievement of a minimum Cumulative Adjusted EBITDA over the Fiscal Years 2017-2019. The reporting person was able to earn PRSUs ranging from 100% to 300% of the target award amount.

SEC source: 0001375852-20-000001 · edgardoc.xml · nonDerivative · entry 2

Sanzone Virginia Ruth · CIK 0001669639 · VP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,542

SEC source: 0001375852-20-000001 · edgardoc.xml · nonDerivative · entry 1

Sanzone Virginia Ruth · CIK 0001669639 · VP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,389

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001410442-20-000002 · edgardoc.xml · derivative · entry 3

Jain Vivek · CIK 0001410442 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,934 shares

Expires 2019-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: These Securities are Performance-based Restricted Stock Units (PRSU).

F2 · derivative.exercise_price: There is neither a purchase price nor an exercise price for the PRSUs.

F3 · shares: Each PRSU reflects the contingent right to receive a variable number of shares of common stock based on achieving performance goals. At the determination date, based on certification of the achievement of the performance criteria, the reporting person earned 300% of the target award amount.

F4 · derivative.exercise_date: These PRSUs were granted on March 27, 2017. The vesting for this performance-based restricted stock unit ("PRSU") award was dependent upon the achievement of a minimum Cumulative Adjusted EBITDA over the Fiscal Years 2017-2019. The reporting person was able to earn PRSUs ranging from 100% to 300% of the target award amount.

SEC source: 0001410442-20-000002 · edgardoc.xml · nonDerivative · entry 2

Jain Vivek · CIK 0001410442 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,403

SEC source: 0001410442-20-000002 · edgardoc.xml · nonDerivative · entry 1

Jain Vivek · CIK 0001410442 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,879

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001073397-19-000008 · edgardoc.xml · nonDerivative · entry 1

LOPEZ GEORGE A · CIK 0001073397 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 339,764

F1 · price: Shares transferred as a bona fide gift without any consideration.

SEC source: 0001375852-19-000011 · edgardoc.xml · derivative · entry 10

Lamb Scott E · CIK 0001375852 · Chief Financial Officer,

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 20,815 shares

Expires 2024-02-24

F7 · derivative.exercise_date: Twenty-five percent of the shares shall vest on each of the first, second,third, and fourth anniversaries of the grant date . Fifty percent of the vested shares shall become exercisable if, during the term of the option, the closing price of the Company's common stock is equal to or more than one-hundred and twenty-five percent of the exercise price per share for thirty consecutive trading days. The remaining fifty percent of the vested shares shall become exercisable if, after the date of award and on or before the expiration date, the closing price of the Company's common stock is equal to or more than one-hundred and fifty percent of eh exercise price for 30 consecutive trading days.

SEC source: 0001375852-19-000011 · edgardoc.xml · nonDerivative · entry 8

Lamb Scott E · CIK 0001375852 · Chief Financial Officer,

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,309

F6 · price: he price reported in Column 4 is an average weighted price. These shares were sold in multiple transactions at prices ranging from $179.18 to $179.19, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0001375852-19-000011 · edgardoc.xml · nonDerivative · entry 7

Lamb Scott E · CIK 0001375852 · Chief Financial Officer,

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,482

F5 · price: The price reported in Column 4 is an average weighted price. These shares were sold in multiple transactions at prices ranging from $178.00 to $178.65, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0001375852-19-000011 · edgardoc.xml · nonDerivative · entry 6

Lamb Scott E · CIK 0001375852 · Chief Financial Officer,

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,386

F4 · price: The price reported in Column 4 is an average weighted price. These shares were sold in multiple transactions at prices ranging from $177.00 to $177.90, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0001375852-19-000011 · edgardoc.xml · nonDerivative · entry 5

Lamb Scott E · CIK 0001375852 · Chief Financial Officer,

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,124

SEC source: 0001375852-19-000011 · edgardoc.xml · derivative · entry 9

Lamb Scott E · CIK 0001375852 · Chief Financial Officer,

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,815

Underlying: Common Stock · 9,185 shares

Expires 2024-02-24

F7 · derivative.exercise_date: Twenty-five percent of the shares shall vest on each of the first, second,third, and fourth anniversaries of the grant date . Fifty percent of the vested shares shall become exercisable if, during the term of the option, the closing price of the Company's common stock is equal to or more than one-hundred and twenty-five percent of the exercise price per share for thirty consecutive trading days. The remaining fifty percent of the vested shares shall become exercisable if, after the date of award and on or before the expiration date, the closing price of the Company's common stock is equal to or more than one-hundred and fifty percent of eh exercise price for 30 consecutive trading days.

SEC source: 0001375852-19-000011 · edgardoc.xml · nonDerivative · entry 4

Lamb Scott E · CIK 0001375852 · Chief Financial Officer,

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,309

F3 · price: All shares sold were sold at the exact price disclosed.

SEC source: 0001375852-19-000011 · edgardoc.xml · nonDerivative · entry 3

Lamb Scott E · CIK 0001375852 · Chief Financial Officer,

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,320

F2 · price: The price reported in Column 4 is an average weighted price. These shares were sold in multiple transactions at prices ranging from $181.00 to $181.15, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0001375852-19-000011 · edgardoc.xml · nonDerivative · entry 2

Lamb Scott E · CIK 0001375852 · Chief Financial Officer,

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,361

F1 · price: The price reported in Column 4 is an average weighted price. These shares were sold in multiple transactions at prices ranging from $180.00 to $180.98, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0001375852-19-000011 · edgardoc.xml · nonDerivative · entry 1

Lamb Scott E · CIK 0001375852 · Chief Financial Officer,

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,494

SEC source: 0001073397-19-000006 · edgardoc.xml · derivative · entry 8

LOPEZ GEORGE A · CIK 0001073397 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,438

Underlying: Common Stock · 623 shares

Expires 2021-07-20

F4 · derivative.exercise_date: Options vest and are exercisable as to 25% of the underlying grant one year after the date of grant and in equal monthly installments thereafter for three additional years.

SEC source: 0001073397-19-000006 · edgardoc.xml · nonDerivative · entry 5

LOPEZ GEORGE A · CIK 0001073397 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 348,864

F3 · price: The price reported in Column 4 is an average weighted price. These shares were sold in multiple transactions at prices ranging from $186.00 to $186.31, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

SEC source: 0001073397-19-000006 · edgardoc.xml · nonDerivative · entry 4

LOPEZ GEORGE A · CIK 0001073397 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 349,487

SEC source: 0001073397-19-000006 · edgardoc.xml · derivative · entry 7

LOPEZ GEORGE A · CIK 0001073397 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,061

Underlying: Common Stock · 12,939 shares

Expires 2021-07-20

F4 · derivative.exercise_date: Options vest and are exercisable as to 25% of the underlying grant one year after the date of grant and in equal monthly installments thereafter for three additional years.